SDGR
Schrodinger, Inc. Common Stock
stock NASDAQ

SDGR short squeeze - it's AI drug discovery season!

SDGR squeeze

My AI biotech stocks have been absolutely ripping. SDGR, CAI, GH, NTRA, TEM to name a few. Not advice.

What happens if big Pharma discovers OMAI?
Remember what Empery Asset Management said about withZeta: they had actually used the platform for biopharma due diligence and found it more useful than generic LLMs.
Now look at $SDGR. The market is starting to recognize the value of specialized Scientific AI after Bristol Myers Squibb moved to deploy its AI co-scientist Bunsen.
So here’s the billion-dollar question:
What happens to tiny $LTRN if one day a Novartis, Roche, or another major pharma starts using OMAI?
At this valuation, OMAI doesn’t need to become Schrödinger.
It just needs one serious external validation to completely change the conversation.
Webcast announced for september!
Today’s +13% might be nothing. Or maybe the market is finally starting to wake up. 🔥

Following up on my post yesterday: $SDGR is now up roughly 33% over the past month, as the market starts paying more attention to the value of specialized Scientific AI platforms.
The parallels to $LTRN’s OMAI are interesting, but there’s one huge difference:
Schrödinger is getting external validation. OMAI still needs to prove it.
A credible OMAI financing, a named pharma customer, or a meaningful enterprise partnership could change that quickly.
Webcast is imminent (announced for september).
At $LTRN’s tiny valuation, it probably wouldn’t take much.